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Abstract. The purpose of the study was a comparative research in the possibility of using the radiopharmaceuticals 
99mTc-Al2O3 and 99mTc-Nanocis for visualizing sentinel lymph nodes. The measurement of the sizes of 99m??-Al2O3 and 
99m??-Nanocis colloidal particles was performed in seven series of radiopharmaceuticals. The pharmacokinetics of 99m??-
Al2O3 and 99m??-Nanocis was researched on 50 white male rats. The possibility of the use of 99m??-Al2O3 and 99m??-
Nanocis for lymphoscintigraphy was studied in the experiments on 12 white male rats. The average dynamic diameter of 
the sol particle was 52–77 nm for 99m??-Al2O3 and 16.7–24.5 nm for 99m??-Nanocis. Radiopharmaceuticals accumulated 
in the inguinal lymph node in 1 hour after administration; the average uptake of 99mTc-Al2O3 was 8.6% in it, and the 
accumulation of 99mTc-Nanocis was significantly lower—1.8% (p < 0.05). In all study points the average uptake of 
99mTc-Al2O3 in the lymph node was significantly higher than 99mTc-Nanocis accumulation. The results of dynamic 
scintigraphic studies in rats showed that 99mTc-Al2O3 and 99mTc-Nanocis actively accumulated into the lymphatic system. 
By using 99mTc-Al2O3 inguinal lymph node was determined in 5 minutes after injection and clearly visualized in all the 
animals in the 15th minute, when the accumulation became more than 1% of the administered dose. Further observation 
indicated that the 99mTc-Al2O3 accumulation reached a plateau in a lymph node (average 10.5%) during 2-hour study and 
then its accumulation remained practically at the same level, slightly increasing to 12% in 24 hours. In case of 99mTc-
Nanocis inguinal lymph node was visualized in all animals for 15 min when it was accumulated on the average 1.03% of 
the administered dose. Plateau of 99mTc-Nanocis accumulation in the lymph node (average 2.05%) occurred after 2 hours 
of the study and remained almost on the same level (in average 2.3%) for 24 hours. Thus, the experimental study of a 
new domestic radiopharmaceutical showed that the 99mTc-Al2O3 accumulates actively in the lymph nodes several times as 
compared to the imported analogue and its practical application will facilitate intraoperative identification of sentinel 
lymph nodes. 
INTRODUCTION 
In recent years radionuclide techniques have proven to identify the sentinel lymph nodes (SLN) which are the 
first lymph nodes on the path of lymph drainage from a malignant tumor. These nodes, filtering afferent lymph, 
become a “trap” for cancer cells, and that is why SLN biopsy followed by histological examination is an objective 
diagnostic criterion for the lymphatic metastasis detection. It is believed that if the SLN are not affected by 
metastatic disease all other regional lymph nodes remain intact [1–7]. 
The world practice has considerable experience in relation to radionuclide visualization of SLN at melanoma and 
breast cancer. For the tumors in other locations (lungs, head, neck, gastrointestinal tract and uterus) the effectiveness 
of this method is studied in scientific research [1–3, 6]. 
Optimal radiopharmaceuticals to identify SLN is the colloid labeled with technetium-99m [1, 6]. In Russian 
Federation to identify the SLN colloidal rhenium sulphide (99mTc-Nanocis, CIS bio International) has been applied. 
The main disadvantage of this radiopharmaceutical is the low level of accumulation in the SLN (1.5–2% of the 
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administered dose) and redistribution to lymph nodes of the 2nd and 3rd orders, which reduces the specificity of 
SLN visualization [1, 3, 6, 7]. 
Currently, in the Russian Federation there are no registered radiopharmaceuticals for SLN imaging. In this 
regard, the Tomsk Cancer Research Institute and Tomsk Polytechnic University developed the original 
radiopharmaceutical based on aluminum oxide (99mTc-Al2O3) labeled with technetium-99m (the project 
No. 16.N08.12.1011 “Preclinical studies of new lymphotropic radiopharmaceutical labeled by technetium-99m 
aluminum oxide” Federal Program “Development of the Russian Federation, the pharmaceutical and medical 
industry period up to 2020 and beyond“).   
The aim of present investigation was a comparative study of the possibility of using the radiopharmaceuticals 
99mTc-Al2O3 and 99mTc-Nanocis for visualizing sentinel lymph nodes in the experiment. 
MATERIAL AND METHODS 
The measurement of the sizes of 99m??-Al2O3 and 99m??-Nanocis colloidal particles was performed in seven 
series of radiopharmaceuticals on apparatus NICOMP 380 ZLS (company PSS NICOMP, USA). 
The pharmacokinetics of 99m??-Al2O3 and 99m??-Nanocis was researched on white male rats “Wistar” 
weighing 200–250 g; the radiopharmaceuticals were injected between the first and second fingers of the hind paw 
subcutaneously in a dose of 30 MBq. Before the injection of radiotracer the animals were anesthetized with ethyl 
ether. The volume of the injected dose was 0.1 ml (volume activity is 300 MBq/ml). The animals were decapitated 
in groups of 10 individuals (5 rats for each radiopharmaceutical) in 1, 2, 3, 5 and 24 h after injection of the 
radiopharmaceuticals. 
The recovered organs and tissues were packed into vials for weighing and direct radioactivity measurement. 
Standard radiopharmaceutical and bioassays have the same volume (after weighing vials filled with distilled water 
up to the same level) and the geometric form. The radioassay of blood and internal organs (the contents of the 
radiopharmaceutical as a percentage of the entered radioactivity per 1 ml of blood or 1 g of tissue or organ) was 
performed on the radiometer RIS A1 (Russian Federation). For radiometric studies a differential discriminator was 
set up on the photon peak of 140 keV, with a window width of 20%. According to the results of the radioassay the 
radiopharmaceutical level in inguinal lymph node and injection site was also determined. 
The possibility of the use of 99m??-Al2O3 and 99m??-Nanocis for lymphoscintigraphy was studied in the 
experiments on 12 white male rats “Wistar” (6 rats for each radiopharmaceutical) weighing 300–350 g. Before a 
single subcutaneous injection of radiopharmaceuticals between the first and second fingers of the hind paw at a dose 
of 18–20 MBq and during scintigraphic studies the animals were anesthetized with ethyl ether. All scintigraphic 
studies were performed on the gamma-camera E-CAM-180 (Siemens, USA) with a setting up of a differential 
discriminator on a photon peak of 140 keV, with a window width of 20%, using a parallel low-energy high-
resolution collimator. During the study the animals were put with their ventral surface to the detector of the gamma 
camera so that the whole body of the animal appeared in the picture. Since the introduction, kinetics of the 
distribution of radiopharmaceuticals through the organs and tissues was fixed by step-frame recording within 15 min 
(1 frame per minute), in the matrix of 64?64 pixels. Static scintigraphy was performed in 1, 2, 3 and 24 hours in the 
front and rear projections in the matrix of 256?256 with a set of 500 pulses per position. According to the results of 
the scintigraphic studies the percent of radiopharmaceuticals accumulation in the inguinal lymph node and the 
injection site from administered dose were determined. 
Keeping and participation of the animals in the experiment were performed in accordance with the rules adopted 
by the “European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific 
Purposes” (Strasbourg, 1986). 
The data received were processed by the method of variation statistics using “STATGRAF” numeric package. 
Between-group comparisons were done by using the Wilcoxon rank-sum test. 
RESULTS AND DISCUSSION 
The measurement of the sizes of radioactive particles of 99m??-Al2O3 and 99m??-Nanocis in 7 batches showed 
that the average dynamic diameter of the sol particle was 52–77 nm for 99m??-Al2O3 and 16.7–24.5 nm for 99m??-
Nanocis, which, according to the literature, is quite acceptable for scintigraphic visualization of lymph nodes [1, 3, 
6]. 
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TABLE 1. The content of 99mTc in the organs and tissues of rats at different times after subcutaneous injection of radiotracer 
99mTc-Al2O3 and 99mTc-Nanocis according to direct radiometry 
Time 1 h 2 h 3 h 5 h 24 h 
99mTc-Al2O3 
Injection 
site
(%) 68.3 ± 5.3 57.0 ± 8.7 53.6 ± 5.0 51.1 ± 5.2 46.7 ± 6.7
Lymph node % 8.6 ± 1.1* 10.5 ± 1.6* 11.2 ± 1.6* 11.8 ± 1.9* 12.8 ± 1.4*
Blood %/ml 0.91 ± 0.01 0.26 ± 0.08 0.28 ± 0.08 0.30 ± 0.07 0.31 ± 0.08+
% 0.33 ± 0.15 0.38 ± 0.11 0.45 ± 0.14 0.43 ± 0.12 0.35 ± 0.11
Liver
%/g 0.13 ± 0.06 0.15 ± 0.05 0.18 ± 0.06 0.18 ± 0.05 0.14 ± 0.07
% 3.8 ± 1.2 9.6 ± 1.1 12.1 ± 2.4 16.8 ± 1.8 21.1 ± 1.6
Stomach
%/g 0.32 ± 0.1 0.8 ± 0.09 1.0 ± 0.14 1.4 ± 0.15 1.8 ± 0.14
% 1.5 ± 0.4 2.6 ± 0.6 4.1 ± 0.9 4.3 ± 0.8 4.5 ± 0.9
Spleen 
%/g 0.74 ± 0.2 1.4 ± 0.29 2.1 ± 0.43 2.2 ± 0.4 2.2 ± 0.42
% 0.41 ± 0.11 0.29 ± 0.12 0.67 ± 1.08 0.6 ± 0.07 0.9 ± 0.1
Heart
%/g 0.34 ± 0.1 0.24 ± 0.09 0.56 ± 0.11 0.61 ± 0.06 0.76 ± 0.07
% 0.34 ± 0.12 0.26 ± 0.09 0.15 ± 0.06 0.13 ± 0.02 0.1 ± 0.08
Lung
%/g 0.12 ± 0.05 0.09 ± 0.04 0.06 ± 0.03 0.05 ± 0.04 0.04 ± 0.3
99mTc-Nanocis 
Injection 
site
(%) 66.3 ± 3.15 59.0 ± 4.1 55.5 ± 5.7 53.2 ± 4.9 51.2 ± 4.3
Lymph  
node 
% 1.8 ± 1.2 3.6 ± 2.4 3.6 ± 1.8 3.6 ± 1.7 3.2 ± 1.0
Blood %/ml 0.2 ± 0.1 0.24 ± 0.04 0.27 ± 0.03 0.27 ± 0.07 0.3 ± 0.1
% 1.2 ± 0.2 1.5 ± 0.2 1.5 ± 0.4 1.5 ± 0.7 2.2 ± 0.4
Liver
%/g 0.48 ± 0.1 0.60 ± 0.15 0.62 ± 0.22 0.63 ± 0.31 0.88 ± 0.38
% 6.6 ± 0.3 10.5 ± 0.9 13.9 ± 2.07 16.3 ± 1.9 18.3 ± 1.4
Stomach
%/g 0.55 ± 0.2 0.87 ± 0.21 1.15 ± 0.24 1.35 ± 0.31 1.52 ± 0.29
% 1.3 ± 0.2 2.1 ± 0.3 2.8 ± 0.5 3.3 ± 0.7 3.6 ± 0.6
Spleen 
%/g 0.65 ± 0.1 1.1 ± 0.15 1.4 ± 0.14 1.65 ± 0.2 1.80 ± 0.2
% 0.3 ± 0.1 0.3 ± 0.06 0.31 ± 0.09 0.3 ± 0.11 0.4 ± 0.15
Heart
%/g 0.25 ± 0.09 0.24 ± 0.08 0.25 ± 0.08 0.24 ± 0.06 0.23 ± 0.07
% 0.6 ± 0.1 0.6 ± 0.12 0.61 ± 0.15 0.59 ± 0.14 0.54 ± 0.2
Lung
%/g 0.22 ± 0.09 0.22 ± 0.1 0.23 ± 0.08 0.21 ± 0.06 0.20 ± 0.1
* p < 0.05% compared to 99mTc-Nanocis. 
 
The radiometry of rats’ organs showed that 99mTc-Al2O3 and 99mTc-Nanocis actively withdrew subcutaneous 
injection spot—there was about 2/3 of the administered dose in the spot after 1 hour (Table 1). About half of the 
dose remained in the injection site after 24 hours. Leaving the injection site, the radiopharmaceuticals were 
accumulated in the inguinal lymph node since 1 hour after administration the average accumulation of 99mTc-
Al2O3 was 8.6% in it. The accumulation of 99mTc-Nanocis was significantly lower—1.8% (p < 0.05). During the 
second hour of study the average accumulation of 99mTc-Al2O3 in inguinal lymph node exceeded 10%, and in a day 
it increased gradually to 12.8%.  
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Table 2. The content of 99mTc in the injection site and inguinal lymph node after subcutaneous injection of radiotracer  
99mTc-Al2O3 and 99mTc-Nanocis according to dynamic scintigraphy 
Localization
Time after the 
injection Average accumulation of 
99mTc-Al2O3, %
Average accumulation of 
99mTc-Nanocis, %
5 min 76.8 ± 3.7 82.7 ± 5.0 
15 min 71.3 ± 4.2 67.7 ± 3.0 
1 h 68.2 ± 5.3 55.7 ± 4.8 
2 h 57.0 ± 8.6 50.5 ± 5.1 
3 h 53.5 ± 4.9 47.7 ± 4.6 
Injection site 
24 h 46.7 ± 6.8 35.33 ± 3.3 
5 min 0.9 ± 0.2 0.98 ± 0.22 
15 min 1.19 ± 0.13 1.03 ± 0.22 
1 h 8.6 ± 1.1 1.4 ± 0.86 
2 h 10.5 ± 1.6 2.05 ± 1.67 
3 h 11.1 ± 1.2 2.18 ± 1.57 
Inguinal lymph 
node 
24 h 12.0 ± 1.4 2.31 ± 1.45 
* p < 0.05% compared to 99mTc-Nanocis. 
 
The accumulation of 99mTc-Nanocis after 2 hours reached 3.6%, and fluctuated slightly at this level up to 
24 hours of observation (Table 1). In all study points the average accumulation of 99mTc-Al2O3 in the lymph node 
was significantly higher than 99mTc-Nanocis accumulation. 
Received through the thoracic duct into the blood radiopharmaceuticals were very actively taken up by liver and 
spleen. The hepatic level of the accumulation of 99mTc-Al2O3 rose from 3.8% in 1 h after injection to 21.1% in 
24 hours of the study, for 99mTc-Nanocis these values were 6.6% and 18.3%, respectively. In the spleen, the 
magnitude accumulation of 99mTc-Al2O3 ranged from 1.5% (in 1 hour) to 4.5% (in 24 hours), the level of 
accumulation of 99mTc-Nanocis grew from 1.3% (in 1 hour) to 3.6% (in 24 hours). A slight content of 
radiopharmaceuticals in the heart, lungs and blood was noted, which recorded less than 1% of the injected dose. 
The results of the dynamic scintigraphic studies in rats showed that 99mTc-Al2O3 and 99mTc-Nanocis 
accumulated actively in the lymphatic system from the injection site (Table 2). After 2 hours 57% of the 
administered dose of 99mTc-Al2O3 and 50.5% of 99mTc-Nanocis was in the injection site. After 24 hours less than 
half the dose of the radiopharmaceuticals was in the injection spot. 
By using 99mTc-Al2O3 the inguinal lymph node was determined in 5 min after injection and clearly visualized in 
all the animals at the 15th min, when the accumulation became more than 1% of the administered dose. Further 
observation indicated that the 99mTc-Al2O3 accumulation reached a plateau in a lymph node (10.5% on average) for 
2-hour study (Fig. 1), and then its accumulation remained practically at the same level, slightly increasing to 12% in 
24 hours. In the case of 99mTc-Nanocis the inguinal lymph node visualized in all the animals in 15 min when it was 
accumulated on the average 1.03% of the administered dose. 
The plateau of 99mTc-Nanocis accumulation in the lymph node (2.05% on average) occurred in 2 hours of the 
study (Fig. 1) and remained almost at the same level (2.3% on average) to 24 hours. 
In oncology practice the spots of radiopharmaceutical injections are often located in close proximity to the 
sentinel lymph node, making it difficult to visualize [1, 6]. 
We have established a multiple higher accumulation of 99mTc-Al2O3 in SLM in comparison with the import 
analogue. Considering this fact the clinical use of new domestic radiopharmaceutical will facilitate intraoperative 
identification of such nodes. 
CONCLUSIONS 
Thus, the experimental study of a new domestic radiopharmaceutical showed that the 99mTc-Al2O3 accumulates 
several times more actively in the lymph nodes as compared to the imported analogue and its practical application 
will facilitate intraoperative identification of SLN. 
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(a) (b) 
FIGURE 1. Scintigrams rats performed through 2 hours after injection of 99mTc-Al2O3 (a) and 99mTc-Nanocis (b).  
A—The level of radioactivity in the injection point (IP)—56% of the injected dose, in the inguinal lymph  
node (LN)—11%. B—bladder. B—The level of radioactivity in the injection point (IP)—61.3%  
of the injected dose, in the inguinal lymph node (LN)—3.5% 
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